There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xenon (XENE – Research Report), Progyny (PGNY – Research Report) and Regulus (RGLS – Research Report) with bullish sentiments.
Xenon (XENE)
Jefferies analyst Andrew Tsai maintained a Buy rating on Xenon yesterday and set a price target of $60.00. The company’s shares closed last Monday at $40.48.
According to TipRanks.com, Tsai is a 3-star analyst with an average return of
Xenon has an analyst consensus of Strong Buy, with a price target consensus of $57.92, a 41.1% upside from current levels. In a report issued on May 9, RBC Capital also maintained a Buy rating on the stock with a $55.00 price target.
See today’s best-performing stocks on TipRanks >>
Progyny (PGNY)
In a report issued on May 10, Michael Cherny from Leerink Partners reiterated a Buy rating on Progyny, with a price target of $31.00. The company’s shares closed last Monday at $27.40, close to its 52-week low of $23.90.
According to TipRanks.com, Cherny is a 3-star analyst with an average return of
Currently, the analyst consensus on Progyny is a Strong Buy with an average price target of $39.29, a 41.6% upside from current levels. In a report issued on April 26, Barclays also maintained a Buy rating on the stock with a $48.00 price target.
Regulus (RGLS)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Regulus on May 9 and set a price target of $6.00. The company’s shares closed last Monday at $2.09.
According to TipRanks.com, Schwartz is a 1-star analyst with an average return of
Currently, the analyst consensus on Regulus is a Strong Buy with an average price target of $7.25, which is a 228.1% upside from current levels. In a report issued on May 6, Canaccord Genuity also maintained a Buy rating on the stock with a $11.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on XENE:
- Xenon Pharmaceuticals price target lowered to $50 from $51 at Wedbush
- Xenon Pharmaceuticals price target lowered to $60 from $62 at Citi
- Xenon Pharmaceuticals Advances Drug Trials
- Xenon Pharmaceuticals: Engaging Investors with Regular Updates
- Xenon Pharmaceuticals reports Q1 EPS (62c), consensus (66c)
